CanBas Co., Ltd. (4575.T)
JPY 957.0
(-2.35%)
JPY 957.0
(-2.35%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 278 Million JPY | -71.22% |
| 2022 | 965.96 Million JPY | 14.12% |
| 2021 | 846.43 Million JPY | 28.91% |
| 2020 | 656.61 Million JPY | -2.98% |
| 2019 | 676.8 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q4 | 707.42 Million JPY | 323.1% |
| 2023 Q1 | 194.53 Million JPY | -26.94% |
| 2023 FY | 1.26 Billion JPY | 30.65% |
| 2023 Q3 | 167.2 Million JPY | -13.31% |
| 2023 Q2 | 192.87 Million JPY | -0.85% |
| 2022 Q2 | 238.46 Million JPY | -23.83% |
| 2022 FY | 965.96 Million JPY | 14.12% |
| 2022 Q4 | 266.27 Million JPY | 79.72% |
| 2022 Q3 | 148.15 Million JPY | -37.87% |
| 2022 Q1 | 313.07 Million JPY | 0.0% |
| 2021 FY | 846.43 Million JPY | 28.91% |
| 2020 FY | 656.61 Million JPY | -2.98% |
| 2019 FY | 676.8 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | 78.357% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | 51.804% |
| GNI Group Ltd. | 9.32 Billion JPY | 97.018% |
| Linical Co., Ltd. | 2.7 Billion JPY | 89.723% |
| Trans Genic Inc. | 2.15 Billion JPY | 87.129% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | 81.357% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 90.948% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 85.029% |
| AnGes, Inc. | 8.9 Billion JPY | 96.877% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | 70.522% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 98.551% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | 32.686% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | 71.498% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 89.173% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | 75.647% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 84.708% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 82.666% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 88.29% |
| PeptiDream Inc. | 9.68 Billion JPY | 97.13% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 85.821% |
| Ribomic Inc. | 1.1 Billion JPY | 74.857% |
| SanBio Company Limited | 4.53 Billion JPY | 93.875% |
| Healios K.K. | 3.48 Billion JPY | 92.028% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | 75.925% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 79.168% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 80.192% |
| StemRIM | 2.07 Billion JPY | 86.609% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 85.842% |
| FunPep Company Limited | 313.82 Million JPY | 11.414% |
| Kringle Pharma, Inc. | 958.01 Million JPY | 70.982% |
| Stella Pharma Corporation | 963.98 Million JPY | 71.161% |
| TMS Co., Ltd. | 943.25 Million JPY | 70.528% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | 74.494% |
| Cuorips Inc. | 598.11 Million JPY | 53.521% |
| K Pharma,Inc. | 543.94 Million JPY | 48.892% |
| Takara Bio Inc. | 23.9 Billion JPY | 98.837% |
| ReproCELL Incorporated | 1.51 Billion JPY | 81.638% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | 76.52% |
| StemCell Institute Inc. | 1.16 Billion JPY | 76.078% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 81.738% |
| CellSeed Inc. | 804.93 Million JPY | 65.463% |